Filing Flows

Filing Flows › Intellia Therapeutics (NTLA) › Next earnings date

Intellia Therapeutics (NTLA) earnings: missed the estimate

Intellia Therapeutics (NTLA) reported on Nov 5, 2026 and missed the EPS estimate: −$0.91 against −$0.79 (-15.8%). Revenue was $7.2M for Q3 2026, -48% year over year. It beat the EPS estimate in 60% of the quarters on record.

Last result−15.8% vs estimate
Beat rate60%

The last report

Intellia Therapeutics reported revenue of $7.2M for the third quarter 2026 (-48% Y/Y), net loss $127M. How it makes money → · Every quarter →

Intellia Therapeutics: EPS against the estimate, last 5 reportsIntellia Therapeutics: EPS against the estimate, last 5 reportsEstimateReported−$0.98−$0.92Nov 25−$0.96−$0.83Feb 26−$0.90−$0.81May 26−$0.78−$0.80Aug 26−$0.79−$0.91Nov 26
Latest (Nov 26): Estimate −$0.79, Reported −$0.91.

Intellia Therapeutics' latest quarter

Intellia Therapeutics, Q3 2026: revenue $7.2M (-48% year over year), net loss $127M, operating cash flow −$85.4M. The chart follows the revenue to costs, profit and cash.

Questions

Did Intellia Therapeutics beat earnings?

Intellia Therapeutics (NTLA) reported on Nov 5, 2026 and missed the EPS estimate: −$0.91 against −$0.79 (-15.8%).

When does NTLA report earnings?

The next date is not set yet.

Does Intellia Therapeutics usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.